TRMT5

Across TCGA pan-cancer cohorts, TRMT5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRMT5 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRMT5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRMT5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where TRMT5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.737	0.850	.026	9	view →
HNSC	DFS	Median	IV	0.805	0.564	.008	6	view →
LSCC	DFS	Tertile	II,III,IV	0.862	0.556	.023	3	view →
CCRCC	OS	Median	All	0.898	0.782	.046	1	view →
GBM	OS	Median	All	0.468	0.308	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRMT5–PDAC (DFS)

Open the PDAC breakdown →